Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 167

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial

de Zeeuw, Dick, Anzalone, Deborah A, Cain, Valerie A, Cressman, Michael D, Heerspink, Hiddo J Lambers, Molitoris, Bruce A, Monyak, John T, Parving, Hans-Henrik, Remuzzi, Giuseppe, Sowers, James R, Vidt, Donald G · 2015 · The Lancet Diabetes & Endocrinology

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s2213-8587(14)70246-3

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Research works printed but not linked: 23

  1. Gansevoort, 2004, Trends in the incidence of treated end-stage renal failure in The Netherlands: hope for the future?, Kidney Int Suppl, 92, S7, 10.1111/j.1523-1755.2004.09202.x · DOI
  2. 1997, Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy, Lancet, 349, 1857, 10.1016/S0140-6736(96)11445-8 · DOI · Paper page
  3. de Zeeuw, 2009, How to improve renal outcome in diabetes and hypertension— the importance of early screening for and treatment of microalbuminuria, Eur Nephrol, 3, 13
  4. Collins, 2009, United States Renal Data System 2008 Annual Data Report, Am J Kidney Dis, 53, S1
  5. Campese, 2007, HMG-CoA reductase inhibitors and the kidney, Kidney Int, 71, 1215, 10.1038/sj.ki.5002174 · DOI
  6. Strippoli, 2008, Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials, BMJ, 336, 645, 10.1136/bmj.39472.580984.AE · DOI · Paper page
  7. Haynes, 2014, Effects of lowering LDL cholesterol on progression of kidney disease, J Am Soc Nephrol, 25, 1825, 10.1681/ASN.2013090965 · DOI · Paper page
  8. Levey, 2000, A simplified equation to predict glomerular filtration rate from serum creatinine (abstract), J Am Soc Nephrol, 11, 155A
  9. Grubb, 2005, Simple cystatin C-based prediction equations for glomerular filtration rate compared with the Modification of Diet in Renal Disease prediction equation for adults and the Schwartz and the Counahan-Barratt prediction equations for children, Clin Chem, 51, 1420, 10.1373/clinchem.2005.051557 · DOI · Paper page
  10. Navaneethan, 2009, HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis, Cochrane Database Syst Rev, 15
  11. Savarese, 2013, Effects of atorvastatin and rosuvastatin on renal function: a meta-analysis, Int J Cardiol, 167, 2482, 10.1016/j.ijcard.2012.05.010 · DOI
  12. Kose, 2014, Effects on serum uric acid by difference of the renal protective effects with atorvastatin and rosuvastatin in chronic kidney disease patients, Biol Pharm Bull, 37, 226, 10.1248/bpb.b13-00418 · doi:10.1248/bpb.b13-00418
  13. DiNicolantonio, 2013, Statin wars: the heavyweight match—atorvastatin versus rosuvastatin for the treatment of atherosclerosis, heart failure, and chronic kidney disease, Postgrad Med, 125, 7, 10.3810/pgm.2013.01.2620 · DOI
  14. Shepherd, 2007, Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study, Clin J Am Soc Nephrol, 2, 1131, 10.2215/CJN.04371206 · DOI · Paper page
  15. Shepherd, 2004, Safety of rosuvastatin, Am J Cardiol, 94, 882, 10.1016/j.amjcard.2004.06.049 · DOI
  16. Vidt, 2004, Rosuvastatin-induced arrest in progression of renal disease, Cardiology, 102, 52, 10.1159/000077704 · DOI
  17. Guthrie, 2007, The safety of rosuvastatin: effects on renal and hepatic function, Expert Opin Drug Saf, 6, 573, 10.1517/14740338.6.5.573 · DOI
  18. Stein, 2012, Renal safety of intensive cholesterol-lowering treatment with rosuvastatin: a retrospective analysis of renal adverse events among 40,600 participants in the rosuvastatin clinical development program, Atherosclerosis, 221, 471, 10.1016/j.atherosclerosis.2011.12.011 · DOI
  19. Crouse, 2007, Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial, JAMA, 297, 1344, 10.1001/jama.297.12.1344 · DOI · Paper page
  20. Ridker, 2010, J Am Coll Cardiol, 55, 1266, 10.1016/j.jacc.2010.01.020 · DOI · Paper page
  21. Guder, 2008, Clinical role of urinary low molecular weight proteins: their diagnostic and prognostic implications, Scand J Clin Lab Invest Suppl, 241, 95, 10.1080/00365510802150174 · DOI
  22. Sorof, 2006, Effect of rosuvastatin or atorvastatin on urinary albumin excretion and renal function in type 2 diabetic patients, Diabetes Res Clin Pract, 72, 81, 10.1016/j.diabres.2005.09.004 · DOI
  23. Gaspari, 1995, Plasma clearance of nonradioactive iohexol as a measure of glomerular filtration rate, J Am Soc Nephrol, 6, 257, 10.1681/ASN.V62257 · DOI · Paper page

Cited by

See all 167

Metadata

Authors
de Zeeuw, D., Anzalone, D. A., Cain, V. A., Cressman, M. D., Heerspink, H. J. L., Molitoris, B. A., Monyak, J. T., Parving, H.-H., Remuzzi, G., Sowers, J. R., & Vidt, D. G.
Venue
The Lancet Diabetes & Endocrinology
Publisher
Elsevier BV
Published
2015-03
Volume
3
Issue
3
Pages
181-190
ISSN
2213-8587 (ISSN-L)
OpenAlex
W2030853351
Cited by
167
References
6
FWCI
14.97
Type
journal article
Language
en
Open access
closed
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Funders
AstraZeneca

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial. https://app.cochat.ai/papers/10.1016/s2213-8587(14)70246-3
The paper
de Zeeuw, D., Anzalone, D. A., Cain, V. A., Cressman, M. D., Heerspink, H. J. L., Molitoris, B. A., Monyak, J. T., Parving, H.-H., Remuzzi, G., Sowers, J. R., & Vidt, D. G. (2015). Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial. The Lancet Diabetes & Endocrinology. https://doi.org/10.1016/s2213-8587(14)70246-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.